Document:

Exhibit 10.57
NABRIVA THERAPEUTICS PLC
Restricted Share Unit Agreement
Granted Under 2020 Share Incentive Plan
​
This Restricted Share Unit Agreement (this “Agreement”) is made between Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), and the Participant pursuant to the 2020 Share Incentive Plan (as amended from time to time, the “Plan”).
 ​
Notice of Grant
​
I.Participant Information
	Participant:
	​

	Participant Address:
	​

​
II.Grant Information
	Grant Date:
	​

	Number of Restricted Share Units:
	​

​
III.Vesting Table
	Vesting Date 
	Number of Restricted Share Units that Vest

	​
	​

	​
	​

​
This Agreement includes this Notice of Grant and the following Exhibits and Schedules, which are expressly incorporated by reference in their entirety herein:
​
Exhibit A – General Terms and Conditions
Exhibit B – Nabriva Therapeutics plc 2020 Share Incentive Plan
Schedule 1 – Vesting Schedule
Schedule 2 – Additional Terms and Conditions
​
IN WITNESS WHEREOF, the parties hereto have executed this Agreement.
​
	NABRIVA THERAPEUTICS PLC
​
__________________________
Name:
Title:
	PARTICIPANT
​
​
__________________________
Name:
	​

​
​
​

Restricted Share Unit Agreement
2020 Share Incentive Plan
Exhibit A
General terms and Conditions
For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:
1.Grant of Restricted Share Units.  This Agreement evidences the grant by the Company, on the grant date (the “Grant Date”) set forth in the Notice of Grant that forms part of this Agreement (the “Notice of Grant”), to the Participant, subject to the terms and conditions set forth in this Agreement and in the Company’s 2020 Share Incentive Plan (as amended from time to time, the “Plan”), of an award with respect to the number of restricted share units (the “RSUs”) set forth in the Notice of Grant.  Each RSU granted hereunder represents the right to receive one ordinary share of the Company (an “Ordinary Share”) upon vesting of the RSU, subject to the terms and conditions set forth herein; provided, however, that if the Company’s shareholders do not approve an increase to the number of Ordinary Shares available for issuance under the Plan (the “Share Pool Increase”) at the Company’s 2022 Annual General Meeting of Shareholders (the “2022 AGM”), then each RSU represents the right to receive, upon vesting, cash in an amount equal to the fair market value of an Ordinary Share as of the vesting date, subject to the terms and conditions set forth herein. For the avoidance of doubt, in the event that the Share Pool Increase is not approved by Company shareholders at the 2022 AGM, no Ordinary Shares shall be issued upon vesting of this award of RSUs and if the Share Pool Increase is approved by Company shareholders at the 2022 AGM, then only Ordinary Shares and not cash shall be issued upon vesting of this award of RSUs. 
1.Vesting.
(a)The RSUs shall vest in accordance with the Vesting Table set forth in the Notice of Grant.  
(b)Upon the vesting of the RSUs, the Company will deliver to the Participant, for each RSU that becomes vested, one Ordinary Share, or, if the Company’s shareholders do not approve the Share Pool Increase at the 2022 AGM, cash in an amount equal to the fair market value of an Ordinary Share on the date of vesting, subject to the payment of any taxes pursuant to Section 4.  Each Ordinary Share, or, if applicable, the cash equivalent thereof, will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date.   
2.Forfeiture of Unvested RSUs Upon Cessation of Service.
In the event that the Participant ceases to perform services to the Company for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs, any Ordinary Shares, or the cash equivalent thereof, as applicable, that may have been issuable with respect thereto.  If the Participant provides services to a 

subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.
3.Tax Matters. 
(a)Acknowledgments; No Section 83(b) Election.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant’s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to participation in the Plan and legally applicable to the Participant (“Tax-Related Items”) relating to the RSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant’s Tax-Related Items that may arise in connection with the grant, vesting and/or settlement of the RSUs and to the extent the RSUs are settled in Ordinary Shares, the subsequent sale of any Ordinary Shares acquired pursuant to the settlement of the RSUs and the receipt of any dividends thereon.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code, as amended, is available with respect to the RSUs and that the Company is under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant becomes subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, as applicable, the Participant acknowledges that the Company may be required to withhold or account for Tax-Related Items in more than one jurisdiction. 
(b)Withholding.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other Tax-Related Items of any kind (including Tax-Related Items of jurisdictions outside the United States, as applicable) required by law to be withheld with respect to the RSUs.  To the extent the RSUs are to be settled with Ordinary Shares, the Participant may satisfy such Tax-Related Items by instructing the Company to withhold a number of Ordinary Shares having a fair market value (valued in the manner determined by (or in a manner approved by) the Board) on the applicable vesting date equal to the Tax-Related Items, based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income. If the Participant does not instruct the Company to withhold Ordinary Shares to satisfy any applicable Tax-Related Items, or if the RSUs are otherwise settleable in cash, then the Participant agrees that if under applicable law the Participant will owe Tax-Related Items at such time on any portion of the RSUs the Company shall be entitled to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following:
		(1)
	immediate payment from the Participant of the amount to be withheld by the Company; or

		(2)
	withholding from wages or other cash compensation paid to the Participant by the Company.

​
To the extent the RSUs shall be settled upon vesting with Ordinary Shares, the Company shall not deliver any Ordinary Shares to the Participant until it is satisfied that all required withholdings have been made and the Participant has complied with the above and applicable obligations in connection with Tax-Related Items. 
​
4.Transfer Restrictions; Clawback.

(a)The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of or encumber, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Ordinary Shares or, if applicable, the cash equivalent thereof, to any transferee to whom the such RSUs have been transferred in violation of any of the provisions of this Agreement.
(b)In accepting this award of RSUs, the Participant agrees to be bound by any clawback policy that the Company has adopted or may adopt in the future.
5.Rights as a Shareholder.  The Participant shall have no rights as a shareholder of the Company with respect to any Ordinary Shares that may be issuable with respect to the RSUs unless and until Ordinary Shares are issued to the Participant following the vesting of the RSUs.  
6.Provisions of the Plan. This Agreement is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is attached hereto as Exhibit B.  
7.Miscellaneous.
(a)No Right to Continued Service/Compensation for Loss.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company. Under no circumstances will the Participant ceasing to be an employee of the Company be entitled to compensation for any loss of any right or benefit or prospective right or benefit under the Plan which the Participant might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or other breach of contract or by way of compensation for loss of office or otherwise howsoever.
(b)Section 409A.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Internal Revenue Code and the Treasury Regulations issued thereunder (“Section 409A”).  The delivery of Ordinary Shares or the cash equivalent thereof, as applicable, on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.
(c)Participant’s Acknowledgements.  The Participant acknowledges that he or she: (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; and (iv) is fully aware of the legal and binding effect of this Agreement.
(d)Governing Law.  This Agreement shall be governed by, except to the extent preempted by other applicable laws (1) with respect to the corporate law requirements applicable to the Company, the validity and authorization of the issuance of Ordinary Shares under the Plan and similar matters, the laws of Ireland (without reference to conflict of law principles thereof) and (2) with respect to all other matters relating to the Plan and Awards, the laws of the State of Delaware, excluding choice-of-law principles of the law of that state.
​

Exhibit B 
Nabriva Therapeutics plc 2020 Share Incentive Plan
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​

Schedule 1
​
Vesting Schedule
​
​
[N/A for Time-Based Awards] 
​
​
​
​
​
​
​

Schedule 2
​
Additional terms to Restricted Share Unit Award Agreement
​
​
Terms and Conditions
This Schedule (the “Schedule”) includes additional terms and conditions that govern the RSUs granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Schedule have the meanings set forth in the Plan and/or the Agreement.
Notifications
This Schedule also includes country-specific information of which you should be aware with respect to your participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of April [__], 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs and, Ordinary Shares, or the cash equivalent thereof, are issued to you or any shares issued upon vesting are sold.
In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result.  Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation.  Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Schedule may not be applicable.
Ireland
Notifications
Director Notification Obligation. If you are a director, shadow director or secretary of the Company or an Irish subsidiary or affiliate of the Company, and you acquire or dispose of an interest under this Agreement comprising more than 1% of the share capital in the Company, you must notify the entity in which you hold that office (whether the Company itself or an Irish subsidiary or affiliate of the Company) in writing within five business days of receiving or disposing of an interest in the Company, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary).Exhibit 10.58
​
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.
SIDE AGREEMENT
to the
Manufacturing Services Agreement
effective as of May 08th, 2017
This Side Agreement (the “Side Agreement”) to the above-mentioned Manufacturing Services Agreement, as assigned by Nabriva Therapeutics GmbH (formerly Nabriva Therapeutics AG) to Nabriva Therapeutics Ireland DAC (the “MSA”), is entered into by and between Patheon UK Ltd, a corporation existing under the laws of United Kingdom, with registered offices at Kingfisher Drive, Covingham, Swindon, SN3 5BZ, UK (“Patheon”) and Nabriva Therapeutics Ireland DAC, an Irish designated activity company, having its registered office at Alexandra House, Office 225/227, The Sweepstakes, Ballsbridge, Dublin 4, D04 C7H2, Ireland (“Customer” or “Nabriva”).  
Each of Patheon and Customer is hereinafter referred as “Party” or together as “Parties”.  This Side Agreement is effective as of January 1st, 2021 (the “Effective Date”).  
Capitalized terms shall have the meaning set forth in the MSA unless otherwise defined herein.
​
WHEREAS, pursuant to Schedule B to the MSA, Customer agreed to order and purchase an annual binding minimum amount of Product following its approval in each relevant Territory so ensuring a certain minimum conversion revenue (i.e:  €[**] in Year 1, and €[**] in Year 2 for the amount of €[**]) (the “Initial Minimum Conversion Revenue”) for Patheon, and that, if such Minimum Conversion Revenue is not met in a given Year, then Customer will pay such an additional sum at the end of that Year that ensures the Minimum Conversion Revenue is paid to Patheon;
WHEREAS, the Product was approved for the US market in August 2019, and in Europe in July 2020;
WHEREAS, in 2020, Nabriva did not order any volume of Product to Patheon and substantially reduced its demand to [**] batches only in 2021;
WHEREAS, in consideration of the above recitals, Nabriva owes Patheon the amount of (i) €[**] for Year 2020 and, (ii) provided that [**] batches of Product are ordered and paid by Nabriva in 2021, the amount of €[**] for Year 2021, equal to the amount of €[**] less the conversion cost of the [**] ordered batched (i.e. €[**]), for an aggregate amount of €[**] (“Amount Due”);
WHEREAS, Nabriva asked Patheon to discount the Amount Due of €[**] (“Discount”), to defer payment of the Amount Due less the Discount, and to revise its Product volume requirements until 2025;
WHEREAS, Patheon has been available to support Customer with the above matter, at the following terms and conditions;
NOW, THEREFORE, in consideration of the premises contained herein, and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
		1.	The above recitals form an integral and substantial part of this Side Agreement.

		2.	The Parties hereby agree to amend Section 8.1 of the MSA to extend the Initial Term of the MSA until 31st December 2025.  All other provisions in Section 8.1 shall remain unchanged.

		3.	Patheon agreed to discount the Amount Due of €[**] (“Discount”) and Nabriva agrees to reimburse Patheon for the Amount Due less the Discount, for an aggregate amount of €[**], according to the following milestones:

		(a)	€[**] by 30th November 2021;

		(b)	€[**] by 31st October 2022;

		(c)	€[**] by 31st October 2023.

		4.	The Parties agree to revise the Price for the Manufacturing Services as follows:

		(i)	each batch of Product manufactured by Patheon in 2021 will be invoiced to Nabriva at the unit price (conversion cost plus components) of €[**];

		(ii)	each batch of Product manufactured by Patheon starting from the 1st January 2022 will be charged by Patheon to Nabriva at the Price per vial set forth in the Schedule B attached to this agreement as ‘Annex 1’ that entirely replaces the Schedule B of the MSA. 

Section 4.2(a) of the MSA shall apply to the Product Price starting from January 1st, 2022.
		5.	Starting from Year 2021, the annual binding minimum amount of Product (“Binding Volume”) that Nabriva is obliged to order and purchase during the Initial Term of the MSA is the following:

	Year
	Binding Volume/Vials

	2021
	[**]

	2022
	[**]

	2023
	[**]

	2024
	[**]

	2025
	[**]

​
It is understood and agreed between the Parties that, should Nabriva (i) not pay in full and at the agreed dates the amounts set forth in Section 3 above, or (ii) not order or purchase the above Binding Volume each Year during the Initial Term, in addition to the provisions of Section 4.2.1 of the MSA and save any other remedy that Patheon may have under the MSA, Patheon shall be entitled to and Nabriva shall be obliged to immediately reimburse Patheon for the amounts (if still due by Nabriva) as follows:
		(i)	 €[**] if the Binding Volume is not ordered and paid in full in Year 2021;

		(ii)	€[**] if the Binding Volume is not ordered and paid in full in Year 2022; 

		(iii)	Any outstanding amount calculated as the difference between the Amount Due, and any other instalment paid by Nabriva in accordance with Section 3 above.

For the sake of clarity, the Parties acknowledge that at the execution date of this Side Agreement, Nabriva has already ordered a paid a batch of Product (#00009) as part of the its 2021 Binding Volume commitment, at the Price applicable in 2020, for a total amount of €[**] instead of the Price agreed in Section 4 above (i.e.  €[**]).  Therefore, upon execution of this Side Agreement, Patheon will be entitled to charge Nabriva for the batch Price difference equal to €[**].
		6.	This Side Agreement constitutes a supplement to the MSA, forms an integral and substantial part thereof and, unless otherwise expressly provided herein, shall be subject to the same terms and conditions of the MSA and duly governed thereby.  Nothing contained in this Side Agreement shall be deemed to constitute a novation of the terms of the MSA, nor affect any of the rights, powers or remedies of the Parties under the MSA, nor constitute a waiver of any provision thereof, except as specifically set forth in this Side Agreement.

		7.	This Side Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the duly authorized representatives of each Party have executed this Side Agreement on the date written above.
	Nabriva Therapeutics Ireland DAC
​
Signature:  /s/ Dan Dolan​ ​​ ​​ ​
​
Name:  Dan Dolan
​
Title:  Director
	Patheon UK Ltd.
​
Signature:  /s/ Andrew Robinson​ ​​ ​
​
Name:  Andrew Robinson
​
Title:  Director

	​
	​

​
​

ANNEX 1
SCHEDULE B
MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE
Long Term Forecast (binding minimum batches) (*)
	Product
	Annual Volume Forecast

		2021
	2022
	2023
	2024
	2025

	Lefamulin Vials
	[**]
	[**]
	[**]
	[**]
	[**]

​
Manufacturing Prices
Bulk Prices:
	Product
	Minimum Order Quantity:  Batch Size (Vials) x Campaign Length (Batches)
	Price Per Bulk Unlabelled Vial

			Component Price
	Conversion Price
	Bulk Price

	Lefamulin Vials
	[**]
	[**]
	[**]
	[**]

	Lefamulin Vials
	[**]
	[**]
	[**]
	[**]

​
[**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]